Why the study?
Anticoagulation in atrial fibrillation patients with significantly reduced renal function remains controversial, although chronic kidney disease significantly increases the risk of stroke and systemic embolism.
Do NOACs improve efficacy, safety, and renal outcomes compared to warfarin in patients with atrial fibrillation and mild to moderate chronic kidney disease?
Do NOACs improve efficacy, safety, and renal outcomes compared to warfarin in patients with atrial fibrillation and mild to moderate chronic kidney disease?
NOACs are preferred over warfarin in patients with atrial fibrillation and mild to moderate chronic kidney disease due to comparable or better efficacy and safety, along with potential renal benefits.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Švarcová et al. (2019) conducted a review in Atrial fibrillation and chronic kidney disease. Novel oral anticoagulants (NOACs) vs. Warfarin was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: